[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
Recruiting now
Conditions studied: Amyloid, Cardiac Amyloidosis, Amyloidosis, Healthy Subjects
In brief
\[18F\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\[18F\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \[18F\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \[18F\]FT8 PET imaging in human subjects.
Key facts
- Study ID
- NCT07232459
- Run by
- Tianjin Medical University
- People needed
- 25
- Starts
- 2025-07-21
- Expected to finish
- 2028-12-20
- Last updated by the study team
- 2025-11-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (enrolling)
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.